MeSH term
Frequency | Condition_Probility | Animals | 65 | 0.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Gene Expression | 8 | 0.0 |
Humans | 428 | 0.0 |
Research Support, Non-U.S. Gov't | 223 | 0.0 |
Antibodies/pharmacology | 2 | 0.0 |
*Aryl Hydrocarbon Hydroxylases | 56 | 6.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 23 | 17.0 |
Enzyme Inhibitors/pharmacology | 19 | 0.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 17 | 24.0 |
Kinetics | 51 | 0.0 |
Microsomes, Liver/drug effects/*enzymology | 5 | 11.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 5 | 10.0 |
Transfection | 11 | 0.0 |
Adolescent | 31 | 0.0 |
Adult | 120 | 0.0 |
Biological Availability | 4 | 1.0 |
Biotransformation | 30 | 5.0 |
Comparative Study | 58 | 0.0 |
Cytochrome P-450 CYP2D6/metabolism | 20 | 50.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 10 | 14.0 |
Dealkylation | 10 | 17.0 |
Dextromethorphan/*pharmacokinetics | 2 | 100.0 |
Female | 144 | 0.0 |
Male | 170 | 0.0 |
Phenotype | 56 | 0.0 |
Reproducibility of Results | 12 | 0.0 |
Acute Disease | 3 | 0.0 |
Aged | 69 | 0.0 |
Cytochrome P-450 CYP1A2/*metabolism | 4 | 5.0 |
Cytochrome P-450 CYP2D6/*metabolism | 10 | 28.0 |
Drug Therapy, Combination | 4 | 0.0 |
Middle Aged | 112 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Cytochrome P-450 Enzyme System/*metabolism | 50 | 10.0 |
Isoenzymes/metabolism | 16 | 3.0 |
Oxidation-Reduction | 23 | 1.0 |
Recombinant Proteins/metabolism | 23 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 59 | 0.0 |
Spectrophotometry, Ultraviolet | 6 | 3.0 |
Substrate Specificity | 35 | 1.0 |
Alleles | 38 | 0.0 |
Base Sequence | 21 | 0.0 |
Cytochrome P-450 CYP2D6/*genetics | 33 | 55.0 |
DNA Primers | 15 | 0.0 |
False Positive Reactions | 2 | 0.0 |
*Gene Frequency | 2 | 0.0 |
Genotype | 89 | 0.0 |
Molecular Sequence Data | 23 | 0.0 |
Polymerase Chain Reaction | 40 | 0.0 |
Polymorphism, Genetic | 42 | 0.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Sensitivity and Specificity | 9 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 3 | 16.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 16 | 10.0 |
*Drug Design | 3 | 3.0 |
In Vitro | 44 | 0.0 |
Mixed Function Oxygenases/genetics/metabolism | 5 | 22.0 |
Pharmacogenetics | 5 | 4.0 |
Carcinogens/pharmacokinetics | 2 | 13.0 |
Cytochrome P-450 CYP1A2/metabolism | 11 | 11.0 |
Cytochrome P-450 CYP2E1/metabolism | 10 | 23.0 |
Rats | 30 | 0.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 2 | 14.0 |
Cytochrome P-450 Enzyme System/*genetics | 37 | 8.0 |
DNA Mutational Analysis | 10 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
English Abstract | 17 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Glutathione Transferase/*genetics | 27 | 4.0 |
Polymorphism, Genetic/*genetics | 11 | 0.0 |
Prognosis | 4 | 0.0 |
Survival Rate | 2 | 0.0 |
Arylamine N-Acetyltransferase/*genetics | 9 | 4.0 |
Xenobiotics/metabolism | 8 | 18.0 |
Anti-Infective Agents/*pharmacology | 2 | 6.0 |
Chromatography, High Pressure Liquid | 33 | 1.0 |
Enzyme Inhibitors/*pharmacology | 21 | 2.0 |
Microsomes, Liver/drug effects/enzymology | 12 | 12.0 |
Recombinant Proteins/antagonists & inhibitors | 3 | 6.0 |
*Steroid 16-alpha-Hydroxylase | 21 | 11.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Databases, Factual | 3 | 1.0 |
Quantitative Structure-Activity Relationship | 3 | 10.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 4 | 22.0 |
Isoenzymes/chemistry/metabolism | 2 | 7.0 |
Models, Molecular | 8 | 0.0 |
Case-Control Studies | 22 | 0.0 |
Child | 13 | 0.0 |
Child, Preschool | 7 | 0.0 |
Cytochrome P-450 CYP1A1/*genetics | 13 | 7.0 |
*Genetic Predisposition to Disease | 9 | 0.0 |
India/ethnology | 2 | 2.0 |
Infant | 6 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Odds Ratio | 5 | 0.0 |
*Polymorphism, Genetic | 41 | 0.0 |
Risk Factors | 25 | 0.0 |
Sex Factors | 11 | 0.0 |
Drug Interactions | 48 | 4.0 |
Inhibitory Concentration 50 | 9 | 3.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 14 | 11.0 |
Isoenzymes/antagonists & inhibitors | 3 | 7.0 |
Microsomes, Liver/drug effects/metabolism | 2 | 4.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 3 | 10.0 |
Baculoviridae/genetics | 3 | 1.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 3 | 4.0 |
Microsomes, Liver/*enzymology/metabolism | 3 | 10.0 |
Recombinant Proteins/biosynthesis | 4 | 0.0 |
Cytochrome P-450 CYP2D6/*genetics/metabolism | 10 | 40.0 |
*Genotype | 5 | 2.0 |
Syndrome | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 2 | 2.0 |
Cytochromes b5/*metabolism | 2 | 33.0 |
Escherichia coli | 3 | 0.0 |
Microsomes, Liver/metabolism | 11 | 6.0 |
Disease Susceptibility | 13 | 1.0 |
Diclofenac/metabolism | 2 | 14.0 |
Dose-Response Relationship, Drug | 14 | 0.0 |
Liver/*enzymology | 6 | 1.0 |
Mixed Function Oxygenases/antagonists & inhibitors | 3 | 10.0 |
Steroid Hydroxylases/antagonists & inhibitors | 4 | 40.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/metabolism | 5 | 38.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/metabolism | 4 | 66.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 7 | 36.0 |
Time Factors | 15 | 0.0 |
Logistic Models | 6 | 0.0 |
Prospective Studies | 6 | 0.0 |
Microsomes, Liver/enzymology | 16 | 7.0 |
Pharmaceutical Preparations/*metabolism | 9 | 9.0 |
Structure-Activity Relationship | 3 | 0.0 |
Isoenzymes/genetics | 7 | 2.0 |
Liver/enzymology | 11 | 1.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Mutagenicity Tests/*methods | 2 | 7.0 |
Mutation | 17 | 0.0 |
Tobacco | 2 | 7.0 |
Cytochrome P-450 Enzyme System/physiology | 3 | 11.0 |
Pharmacokinetics | 8 | 22.0 |
*Sex Characteristics | 2 | 1.0 |
Breast/*enzymology | 2 | 13.0 |
Gene Expression Regulation, Enzymologic | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 10 | 9.0 |
Linkage (Genetics) | 3 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Area Under Curve | 9 | 1.0 |
Hydroxylation/drug effects | 3 | 8.0 |
Microsomes, Liver/*drug effects/enzymology | 3 | 8.0 |
Steroid Hydroxylases/antagonists & inhibitors/metabolism | 2 | 22.0 |
Tolbutamide/metabolism | 2 | 13.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 4 | 16.0 |
Cytochrome P-450 CYP2D6/genetics | 14 | 45.0 |
European Continental Ancestry Group/genetics | 7 | 1.0 |
Mixed Function Oxygenases/genetics | 6 | 15.0 |
Chlorzoxazone/metabolism | 5 | 25.0 |
Mephenytoin/metabolism | 2 | 12.0 |
Metoprolol/metabolism | 2 | 100.0 |
Midazolam/metabolism | 3 | 15.0 |
Mixed Function Oxygenases/metabolism | 18 | 12.0 |
Omeprazole/metabolism | 2 | 25.0 |
Oxidoreductases, N-Demethylating/metabolism | 5 | 9.0 |
Antipsychotic Agents/*pharmacokinetics | 3 | 50.0 |
DNA, Complementary/biosynthesis | 3 | 5.0 |
Haloperidol/*pharmacokinetics | 2 | 100.0 |
Microsomes, Liver/enzymology/*metabolism | 6 | 7.0 |
Cells, Cultured | 9 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Autoantibodies/blood/*immunology | 2 | 5.0 |
Blotting, Western | 11 | 0.0 |
Hepatitis C, Chronic/blood/*immunology | 2 | 50.0 |
Hepatitis, Autoimmune/blood/*immunology | 2 | 100.0 |
Recombinant Proteins/immunology/metabolism | 2 | 4.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Gene Frequency | 17 | 0.0 |
Genetic Predisposition to Disease | 15 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Reference Values | 15 | 0.0 |
Schizophrenia/enzymology/*genetics | 3 | 13.0 |
Depressive Disorder/*drug therapy | 2 | 28.0 |
Mass Fragmentography | 4 | 1.0 |
Mixed Function Oxygenases/*metabolism | 11 | 7.0 |
Saccharomyces cerevisiae/enzymology | 3 | 5.0 |
Microsomes, Liver/*enzymology | 26 | 13.0 |
RNA, Messenger/biosynthesis | 6 | 0.0 |
Aged, 80 and over | 20 | 0.0 |
Analysis of Variance | 6 | 0.0 |
Cytochrome P-450 Enzyme System/drug effects/*metabolism | 2 | 9.0 |
Environmental Exposure | 2 | 1.0 |
Epidemiology, Molecular | 2 | 2.0 |
Pregnancy | 6 | 0.0 |
Regression Analysis | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors | 2 | 13.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors | 3 | 42.0 |
Histamine H1 Antagonists/*pharmacology | 2 | 18.0 |
Tissue Distribution | 5 | 0.0 |
Cytochrome P-450 Enzyme System/*drug effects | 3 | 23.0 |
Drug Combinations | 3 | 0.0 |
Cytochrome P-450 Enzyme System/*chemistry/*metabolism | 3 | 17.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Microsomes, Liver/enzymology/metabolism | 6 | 9.0 |
Models, Chemical | 5 | 1.0 |
Protein Binding | 9 | 0.0 |
Binding, Competitive | 3 | 0.0 |
Caffeine/metabolism | 4 | 14.0 |
Cytochrome P-450 Enzyme System/metabolism | 8 | 3.0 |
Phenacetin/metabolism | 2 | 18.0 |
Steroid Hydroxylases/metabolism | 7 | 11.0 |
Alkylation | 3 | 4.0 |
Cross-Sectional Studies | 2 | 0.0 |
Glutathione Transferase/*genetics/metabolism | 2 | 2.0 |
Acetyltransferases/genetics | 2 | 5.0 |
Glutathione Transferase/genetics | 8 | 2.0 |
Polymorphism, Restriction Fragment Length | 19 | 0.0 |
Anti-Bacterial Agents/*pharmacology | 2 | 1.0 |
Caffeine/blood | 2 | 50.0 |
Cross-Over Studies | 7 | 1.0 |
Theophylline/blood | 2 | 50.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 2 | 14.0 |
Toxicology/*methods | 3 | 42.0 |
Gene Frequency/genetics | 3 | 0.0 |
Mixed Function Oxygenases/*genetics | 18 | 12.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/*physiology | 2 | 66.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*physiology | 3 | 20.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*physiology | 2 | 33.0 |
Cell Line | 12 | 0.0 |
DNA, Complementary | 9 | 0.0 |
England | 2 | 1.0 |
United States | 2 | 0.0 |
B-Lymphocytes/enzymology | 3 | 8.0 |
Cytochrome P-450 CYP1A1/metabolism | 2 | 3.0 |
Microsomes/enzymology | 6 | 5.0 |
Hydroxylation | 19 | 5.0 |
Rats, Sprague-Dawley | 7 | 0.0 |
Steroid Hydroxylases/*metabolism | 2 | 6.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Brain/*enzymology | 3 | 1.0 |
*Pharmacokinetics | 3 | 6.0 |
*Alleles | 3 | 0.0 |
Cytochrome P-450 CYP2E1/genetics | 3 | 7.0 |
Enzyme Activation | 2 | 0.0 |
Japan | 9 | 0.0 |
Binding Sites | 7 | 0.0 |
Coumarins/metabolism | 3 | 12.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/metabolism | 2 | 6.0 |
Molecular Structure | 6 | 0.0 |
*Monoterpenes | 2 | 20.0 |
Spectrophotometry | 2 | 1.0 |
Terpenes/pharmacology | 2 | 7.0 |
Algorithms | 3 | 0.0 |
Mixed Function Oxygenases/*antagonists & inhibitors | 4 | 9.0 |
Indicators and Reagents | 2 | 0.0 |
Testosterone/metabolism | 6 | 4.0 |
Haloperidol/*analogs & derivatives/metabolism | 2 | 100.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Risk Assessment | 3 | 0.0 |
Depressive Disorder/drug therapy | 2 | 33.0 |
Half-Life | 6 | 1.0 |
Drug Evaluation, Preclinical/*methods | 4 | 12.0 |
Aldehyde Dehydrogenase/genetics | 2 | 6.0 |
DNA/genetics | 4 | 0.0 |
Enzymes/*genetics | 2 | 4.0 |
Methyltransferases/genetics | 2 | 11.0 |
Polymorphism, Genetic/genetics | 6 | 0.0 |
Cytochrome P-450 CYP2D6/genetics/*metabolism | 4 | 28.0 |
Mixed Function Oxygenases/genetics/*metabolism | 6 | 12.0 |
Clinical Trials | 4 | 0.0 |
Isoenzymes/*genetics | 5 | 1.0 |
Metabolic Detoxication, Drug/genetics | 3 | 15.0 |
Poland | 2 | 1.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 5 | 17.0 |
Microsomes, Liver/*metabolism | 15 | 8.0 |
Spectrum Analysis, Mass | 6 | 1.0 |
Crystallography, X-Ray | 2 | 0.0 |
Ligands | 4 | 0.0 |
Progesterone/*metabolism | 2 | 5.0 |
Protein Conformation | 5 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Cimetidine/pharmacology | 2 | 9.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 4 | 11.0 |
Ketoconazole/pharmacology | 7 | 7.0 |
DNA/analysis | 3 | 0.0 |
Polymerase Chain Reaction/*methods | 5 | 0.0 |
Cytochrome P-450 Enzyme System/*physiology | 7 | 11.0 |
Hamsters | 2 | 0.0 |
Mixed Function Oxygenases/*physiology | 5 | 16.0 |
Antidepressive Agents/*pharmacology | 3 | 11.0 |
*Hypericum | 3 | 33.0 |
*Plants, Medicinal | 3 | 4.0 |
Lod Score | 2 | 0.0 |
Coumarins/pharmacology | 2 | 10.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 2 | 7.0 |
Liver/drug effects/enzymology | 3 | 4.0 |
Rabbits | 8 | 0.0 |
Metabolic Clearance Rate | 6 | 1.0 |
Microsomes/*enzymology | 3 | 6.0 |
Pharmaceutical Preparations/metabolism | 8 | 24.0 |
*Gene Expression | 2 | 0.0 |
Catalysis | 5 | 0.0 |
Cytochrome P-450 CYP2D6/*physiology | 3 | 50.0 |
Dextromethorphan/*metabolism | 2 | 50.0 |
Swine | 3 | 0.0 |
Biotransformation/*genetics | 2 | 33.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 6 | 13.0 |
Glutathione Transferase/genetics/metabolism | 3 | 2.0 |
*Variation (Genetics) | 2 | 0.0 |
Antidepressive Agents, Second-Generation/*blood | 2 | 100.0 |
Dextromethorphan/pharmacokinetics | 2 | 66.0 |
Isoenzymes/*metabolism | 11 | 3.0 |
Cytochrome P-450 CYP1A2/drug effects | 2 | 100.0 |
Cytochrome P-450 CYP2D6/drug effects | 2 | 100.0 |
Double-Blind Method | 6 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Steroid Hydroxylases/drug effects | 2 | 66.0 |
Enzyme Induction/drug effects | 4 | 1.0 |
Hydrocortisone/urine | 2 | 16.0 |
Dimethyl Sulfoxide/pharmacology | 2 | 2.0 |
Microsomes, Liver/*drug effects/*enzymology | 2 | 40.0 |
DNA, Complementary/*biosynthesis | 4 | 33.0 |
*Ginsenosides | 2 | 22.0 |
Isoenzymes/antagonists & inhibitors/genetics/metabolism | 3 | 21.0 |
Panax/*chemistry | 2 | 18.0 |
Plant Extracts/*pharmacology | 3 | 4.0 |
Saponins/*pharmacology | 2 | 20.0 |
Statistics | 3 | 0.0 |
Isoenzymes/genetics/*metabolism | 3 | 3.0 |
Species Specificity | 7 | 0.0 |
Genetic Predisposition to Disease/genetics | 4 | 0.0 |
Dogs | 4 | 0.0 |
Haplorhini | 2 | 0.0 |
Mice | 6 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 5 | 10.0 |
Indoles/metabolism/pharmacology | 2 | 33.0 |
Oxazines/metabolism | 2 | 9.0 |
Acetylation | 3 | 0.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 4 | 26.0 |
Cytochrome P-450 CYP2D6/genetics/metabolism | 5 | 33.0 |
Isoenzymes/genetics/metabolism | 6 | 4.0 |
Predictive Value of Tests | 2 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Xenobiotics/*metabolism | 8 | 14.0 |
Chronic Disease | 3 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 3 | 17.0 |
Xanthine Oxidase/genetics/metabolism | 2 | 100.0 |
Cytochrome P-450 CYP1A1/genetics | 4 | 4.0 |
*Mutation | 6 | 0.0 |
Smoking/adverse effects | 4 | 1.0 |
Debrisoquin/*metabolism | 8 | 72.0 |
Benzodiazepines | 3 | 14.0 |
Fluvoxamine/pharmacology | 2 | 14.0 |
Serotonin Uptake Inhibitors/pharmacology | 2 | 16.0 |
Macaca fascicularis | 3 | 1.0 |
Methylation | 5 | 0.0 |
Serotonin Uptake Inhibitors/*pharmacokinetics | 2 | 40.0 |
Homozygote | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 6 | 13.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
China | 2 | 0.0 |
Stereoisomerism | 7 | 1.0 |
Caffeine/pharmacokinetics | 2 | 15.0 |
Central Nervous System Stimulants/pharmacokinetics | 2 | 66.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors | 2 | 13.0 |
Cytochrome P-450 CYP2D6/*antagonists & inhibitors | 2 | 22.0 |
Quinidine/pharmacology | 5 | 11.0 |
Quinine/pharmacology | 2 | 15.0 |
Recombinant Proteins/genetics/metabolism | 6 | 0.0 |
Troleandomycin/pharmacology | 2 | 3.0 |
Incidence | 2 | 0.0 |
Smoking/*adverse effects | 4 | 1.0 |
Forensic Medicine/*methods | 2 | 6.0 |
Antipsychotic Agents/metabolism | 2 | 50.0 |
DNA, Complementary/genetics/metabolism | 2 | 4.0 |
Pyrimidines/*metabolism | 2 | 28.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 11 | 9.0 |
Genetic Heterogeneity | 2 | 0.0 |
Neoplasms/*enzymology/genetics | 2 | 20.0 |
Confidence Intervals | 4 | 1.0 |
Immunohistochemistry | 4 | 0.0 |
Laryngeal Neoplasms/*genetics | 2 | 11.0 |
Cytochrome P-450 CYP2E1/*genetics/metabolism | 2 | 9.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 5 | 10.0 |
Drug Administration Schedule | 2 | 0.0 |
Electrocardiography/drug effects | 2 | 6.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Autoradiography | 2 | 0.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 2 | 5.0 |
Midazolam/pharmacokinetics | 2 | 16.0 |
P-Glycoprotein/metabolism | 2 | 3.0 |
Aging/*metabolism | 2 | 0.0 |
Isomerism | 2 | 0.0 |
Debrisoquin/metabolism | 5 | 50.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 2 | 6.0 |
Lung/*enzymology | 2 | 3.0 |
Mucous Membrane/enzymology | 2 | 18.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Tamoxifen/*metabolism | 2 | 22.0 |
*Drug Interactions | 4 | 17.0 |
*Pharmacogenetics | 2 | 4.0 |
Age Factors | 5 | 0.0 |
Cytochrome P-450 CYP2D6 | 44 | 59.0 |
Heterozygote | 3 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
*Phenotype | 4 | 1.0 |
Serotonin Uptake Inhibitors/*pharmacology | 3 | 10.0 |
Immunoblotting | 3 | 0.0 |
Asian Continental Ancestry Group/genetics | 5 | 1.0 |
Cytochrome P-450 CYP2E1/*genetics | 5 | 4.0 |
Mixed Function Oxygenases/drug effects | 2 | 50.0 |
Cloning, Molecular | 5 | 0.0 |
NADPH-Ferrihemoprotein Reductase | 2 | 15.0 |
Schizophrenia/drug therapy/*genetics | 2 | 12.0 |
Point Mutation | 3 | 0.0 |
*Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Steroid 16-alpha-Hydroxylase | 2 | 14.0 |
NADP/pharmacology | 2 | 9.0 |
Terpenes/*pharmacology | 2 | 10.0 |
Gene Deletion | 2 | 0.0 |
Administration, Oral | 3 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Sweden | 2 | 0.0 |
Enzyme Inhibitors/metabolism | 3 | 1.0 |
Autoantibodies/*immunology | 2 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
*Multigene Family | 2 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Ethanolamines/metabolism | 5 | 27.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Microsomes/metabolism | 3 | 2.0 |
Transcription, Genetic | 2 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 2 | 12.0 |
Isoenzymes/biosynthesis/genetics/*metabolism | 2 | 22.0 |
Aging/metabolism | 2 | 1.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/metabolism | 2 | 15.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Cytochrome P-450 CYP2D6/*genetics/physiology | 2 | 100.0 |
Neoplasms/*etiology | 2 | 7.0 |
Psychiatric Status Rating Scales | 2 | 0.0 |
Lung Neoplasms/*genetics | 4 | 1.0 |
Arylamine N-Acetyltransferase/*genetics/metabolism | 2 | 3.0 |
Brain/enzymology | 3 | 1.0 |
Anti-Bacterial Agents/adverse effects | 2 | 22.0 |
Carbon Radioisotopes | 3 | 3.0 |
Cytochrome P-450 CYP1A2/*analysis | 2 | 100.0 |
Antibody Specificity | 4 | 0.0 |
Immune Sera/immunology | 2 | 1.0 |
Rats, Wistar | 5 | 0.0 |
Sertraline | 3 | 30.0 |
Exons | 5 | 0.0 |
Plasmids | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 2 | 13.0 |
Carcinoma, Basal Cell/*epidemiology/genetics | 2 | 100.0 |
NADP/metabolism | 3 | 2.0 |
*Epitope Mapping | 2 | 3.0 |
Serotonin Uptake Inhibitors/pharmacokinetics/*pharmacology | 2 | 100.0 |
Cytochrome P-450 Enzyme System/genetics/*physiology | 2 | 18.0 |
Sex Characteristics | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 2 | 1.0 |
Mutation/*physiology | 2 | 1.0 |
Zimbabwe | 3 | 11.0 |
Drug Monitoring | 2 | 4.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors | 2 | 4.0 |
Enzyme Inhibitors/*metabolism | 2 | 2.0 |
Skin Pigmentation | 2 | 13.0 |
Smoking | 5 | 1.0 |
Risk | 2 | 0.0 |
Pedigree | 3 | 0.0 |
Placenta/*enzymology | 2 | 2.0 |
Receptors, Calcitriol/genetics | 2 | 4.0 |
Mixed Function Oxygenases/*genetics/metabolism | 5 | 12.0 |
Cytochrome P-450 Enzyme System/*analysis | 2 | 10.0 |
Chromatography, High Pressure Liquid/methods | 3 | 2.0 |
Cytochrome P-450 CYP1A2 | 5 | 5.0 |
Cattle | 2 | 0.0 |
DNA, Mitochondrial/genetics | 2 | 4.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Cytochrome P-450 CYP1A1 | 4 | 9.0 |
Oxidoreductases/metabolism | 2 | 2.0 |
Sparteine/*metabolism | 5 | 83.0 |
Cytochrome P-450 CYP2D6/*genetics/*metabolism | 2 | 66.0 |
Sparteine/metabolism | 4 | 66.0 |
DNA Primers/genetics | 3 | 0.0 |
Haplotypes | 3 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Sequence Deletion | 2 | 0.0 |
Fluoxetine/pharmacology | 2 | 33.0 |
Paroxetine/pharmacology | 2 | 66.0 |
Moclobemide | 2 | 50.0 |
Isoenzymes/*physiology | 2 | 6.0 |
Neoplasms/enzymology/*genetics | 3 | 21.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
Glutathione Transferase/genetics/*metabolism | 2 | 14.0 |
Oxidoreductases/genetics/metabolism | 2 | 16.0 |
Cytochrome P-450 CYP2E1 | 2 | 1.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Random Allocation | 2 | 0.0 |
Lung Neoplasms/*enzymology/*genetics | 2 | 16.0 |
Mixed Function Oxygenases/*genetics/*metabolism | 2 | 11.0 |
Solubility | 2 | 0.0 |
Arylamine N-Acetyltransferase/genetics | 2 | 3.0 |
Lung Neoplasms/enzymology/*genetics | 2 | 5.0 |
*Genes, Structural | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 2 | 11.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 2 | 1.0 |
Liver/*metabolism | 3 | 0.0 |
Herb-Drug Interactions | 2 | 25.0 |
Drug Evaluation, Preclinical/methods | 2 | 6.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Substrate Specificity/physiology | 2 | 9.0 |
Intestinal Absorption | 2 | 1.0 |
